雷贝拉唑、泮托拉唑、奥美拉唑四联疗法治疗幽门螺杆菌阳性消化性溃疡的临床疗效比较

Comparison of Clinical Effects of Rabeprazole,Pantoprazole and Omeprazole in Treatment of Helicobacter pylori-Positive Peptic Ulcer

目的比较雷贝拉唑、泮托拉唑、奥美拉唑四联疗法治疗幽门螺杆菌(HP)阳性消化性溃疡的临床疗效。方法选取2015年6月至2018年12月灌云县中医院治疗的HP阳性消化性溃疡的90例患者作为实验对象,将他们分为雷贝拉唑组、泮托拉唑组、奥美拉唑组,每组30例。所有的实验对象均采用四联疗法进行治疗,包括阿莫西林胶囊、克拉霉素分散片、枸橼酸铋钾以及对应的雷贝拉唑、泮托拉唑、奥美拉唑。观察3组患者的溃疡愈合率、HP根除率、不良反应和临床疗效。结果治疗后,雷贝拉唑组的溃疡愈合率、HP根除率、及临床疗效均优于泮托拉唑和奥美拉唑组(P<0.05),3组不良反应发生率差异无统计学意义(P>0.05)。结论治疗HP阳性消化性溃疡最有临床疗效的是雷贝拉唑。

Objective To compare the clinical efficacy of rabeprazole,pantoprazole and omeprazole in the treatment of Helicobacter pylori(HP)-positive peptic ulcer.Methods A total of 90 patients with HP-positive peptic ulcer treated in our hospital from April 2015 to December 2018 were enrolled in the study.They were divided into rabeprazole group,pantoprazole group and omeprazole group,30 cases per group.All subjects were treated with quadruple therapy,including amoxicillin capsules,clarithromycin dispersible tablets,bismuth potassium citrate and the corresponding rabeprazole,pantoprazole and omeprazole,respectively.The ulcer healing rate,HP eradication rate,adverse reactions and clinical efficacy were observed in the three groups.Results There was no significant difference in clinical data and symptoms between the three groups(P>0.05).After treatment,the ulcer healing rate,HP eradication rate and clinical efficacy of the rabeprazole group were better than pantoprazole.Compared with the omeprazole group(P<0.05),there was no significant difference in the incidence of adverse reactions(P>0.05).Conclusion The most clinically effective treatment for HP-positive peptic ulcer is rabeprazole.